Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.
Amgen's biosimilar version of Roche’s top selling cancer drug, Avastin has been approved in the US, making it the first ever cancer biosimilar approved by the FDA.
